TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01706653

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - low

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - medium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - high

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Very low polyphenol fruit based drink (control)
Study: NCT02668341

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional survey study

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional survey study

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional survey study

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional survey study
Study: NCT04210661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prediction software with spell checker
Description: test with prediction software with spell checker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prediction software with spell checker
Description: test with prediction software with spell checker
Study: NCT03469167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEGP003
Description: Application of CEGP003 to peptic ulcer bleeding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Tx
Description: Injection of epinephrine to peptic ulcer bleeding
Study: NCT04436445

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dry cupping
Description: represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life style modification
Description: Life style modification
Study: NCT01043744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Description: Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)
Study: NCT02465476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: treatment pathway organized by telemedicine
Study: NCT01539447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: • Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: • Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
Study: NCT02212665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intense interval training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer+HIIT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased daily activity detected by the pedometer+group intervention
Study: NCT02505373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Description: The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
Study: NCT02854995

Intervention type: PROCEDURE
Group type: OTHER
Intervention: circumcision
Description: (i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preputioplasty with intralesional injection of triamcinolone:
Description: (ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
Study: NCT03725072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
Study: NCT01188941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System Navigator
Description: Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
Study: NCT02664480

Intervention type: OTHER
Intervention: Salivary alpha-Amylases
Description: Investigators will collect Salivary alpha-Amylases before and after ovulation

Intervention type: OTHER
Intervention: Salivary alpha-Amylases
Description: Investigators will collect Salivary alpha-Amylases before and after ovulation
Study: NCT02628444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Sodium chloride 0.9%)
Description: 0.5 mL, Subcutaneous
Study: NCT00784368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ Oral Solution
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ Oral Solution
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ Oral Solution
Description: ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ-IV
Description: 200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCZ-IV
Description: 200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
Study: NCT06375525

Intervention type: DEVICE
Group type: OTHER
Intervention: Janssen's icon Application (App)
Study: NCT01518790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 3350
Description: PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
Study: NCT03567889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daromun
Description: Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients in Arm 2 will receive surgery within 4 weeks from randomisation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Patients in Arm 2 will receive surgery within 4 weeks from randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Study: NCT03128359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo PBSC HCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03567889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Study: NCT00712387

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LapSim simulator
Description: Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
Study: NCT04579666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (APL-2)
Description: Complement (C3) Inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution of equal volume to active arm
Study: NCT01082627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: 250ug/h,Continuous I.V. infusion,maximal 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: common daily practice
Description: common daily practice
Study: NCT02969642

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Argus Migraine Treatment device
Description: treatment of Migraines targeting Sphenopalatine ganglion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argus Migraine Treatment device
Description: treatment of Migraines targeting Sphenopalatine ganglion
Study: NCT00540696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses.
Study: NCT03951610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control lens
Description: contact lens
Study: NCT04387929

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of anti-COVID-19 antibody level
Description: Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
Study: NCT04146337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal microbiota in frozen capsules
Study: NCT03128359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01126190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neugranin
Description: Neugranin will be administered per dose and schedule specified in the arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neugranin
Description: Neugranin will be administered per dose and schedule specified in the arm description.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
Study: NCT02250976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livasupril Cap.160/2mg
Description: Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipilfen cap. 160mg
Description: Micronized fenofibrate 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livaro tab. 2mg
Description: Pitavastatin Ca 2mg
Study: NCT03406208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 1
Description: The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Symptom Management Program 2
Description: The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
Study: NCT02722005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: One-to-one financial coaching focused on credit, debt, savings, and income supports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to referral to social services
Description: Access to referral to a host of social services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to referral to social services
Description: Access to referral to a host of social services.
Study: NCT03323138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex-PRESS and phacoemulsification
Study: NCT01591265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of upper and lower FPM teeth
Description: Extraction of upper and lower FPM teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of lower FPM tooth
Description: Extraction of lower FPM tooth only
Study: NCT01977898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
Study: NCT01709552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Intervention
Description: Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
Study: NCT01405404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training and childcare discount
Description: 12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 12-session group on parenting skills and child behavior management
Study: NCT02301000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota therapy
Description: 60 ml of ACHIM suspension will be administered through a rectal tube

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Peroral metronidazole 400 mg t.i.d. for ten days
Study: NCT03290092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib (GDC0032)
Description: The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib (GDC0032)
Description: The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
Study: NCT03128359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study: NCT02567357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Scheduling
Description: Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: signalling change
Description: Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
Study: NCT03128359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC HCT
Study: NCT00425113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Study: NCT03128359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC HCT